Informatie:
Fout:
ID
12357
Beschrijving
Study description: Study documentation part- Study termination. This is a phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS). Principal Investigator PD Dr. Tobias Grge, University Hospital of Mnster. EudraCT - Nr. 2012-000108-13.
Trefwoorden
Versies (1)
- 11-11-15 11-11-15 -
Geüploaded op
11 november 2015
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination DRKS00004652
Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination
- StudyEvent: ODM
Similar models
Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
date
Item
Date of termination:
date
Center number
Item
Center number:
integer
Item
Reasons for study termination
text
C0008972 (UMLS CUI [1,1])
C0013135 (UMLS CUI [1,2])
C1272707 (UMLS CUI [1,3])
C0013135 (UMLS CUI [1,2])
C1272707 (UMLS CUI [1,3])
CL Item
Revocation of Consent by patient (1)
CL Item
Early ending of the entire study (2)
CL Item
Lack of patient compliance (3)
CL Item
Fall in hemoglobin of more than 2 units [g / dL] from initial value and source of bleeding can not be stopped (4)
CL Item
Decision of the investigator that further participation of the patient in the study is not justifiable (5)
CL Item
Violation of inclusion or exclusion criteria after 1st dose study medication (6)
inclusion criteria; exclusion criteria
Item
Please mention the criteria, if inclusion or exclusion criteria is the reason for study drop out.
text
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,2])